SCHEMBL2117210

SCHEMBL2117210

COc1ccc(S(=O)(=O)Nc2cc(-c3ccc(C#N)cn3)ccc2C)nc1

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.42
STAT3 P40763 1/20 0.41
ALPL P05186 2/20 0.41
ALDH1A1 P00352 3/20 0.40
KDM4E B2RXH2 2/20 0.40
HPGD P15428 2/20 0.40
HTT P42858 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
ACLY P53396 2/20 0.39
PTGER4 P35408 4/20 0.38
SGK1 O00141 1/20 0.37
PIK3CA P42336 3/20 0.37
MTOR P42345 3/20 0.37
CYP2C9 P11712 1/20 0.37
TSHR P16473 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
GHSR Q92847 1/20 0.35
CCR6 P51684 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2118122 0.91 MAPT (0.48) MAPTALDH1A1PTGER4CYP2C9TSHR
SCHEMBL2119029 0.90 ACLY (0.49) MAPTSTAT3ALPLALDH1A1ACLY
SCHEMBL2119308 0.84 ACLY (0.39) MAPTSTAT3ALPLALDH1A1KDM4E
SCHEMBL2118462 0.83 PIK3CA (0.39) MAPTSTAT3ALPLALDH1A1KDM4E
SCHEMBL2118441 0.81 MAPT (0.43) MAPTALDH1A1HPGDPTGER4CYP2C9
SCHEMBL2117738 0.80 ACLY (0.46) MAPTSTAT3ACLYPIK3CAMTOR
SCHEMBL2120060 0.80 HSD11B1 (0.45) MAPTACLYSGK1
SCHEMBL2117835 0.80 MAPT (0.39) MAPTSTAT3ALPLALDH1A1PIK3CA
SCHEMBL2119673 0.80 ACLY (0.43) MAPTSTAT3ACLYSGK1PIK3CA
SCHEMBL2120392 0.80 PIK3CA (0.43) MAPTSTAT3ACLYPIK3CAMTOR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120095012-A1 TOLUIDINE SULFONAMIDES AND THEIR USE ELARA PHARMACEUTICALS GMBH (DE) 2012-04-19 US disclosed
EP-2382190-A1 TOLUIDINE SULFONAMIDES AND THEIR USE AS-INHIBITORS European Molecular Biology Laboratory (EMBL) (DE) 2011-11-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120095012-A1 TOLUIDINE SULFONAMIDES AND THEIR USE HIF1A, HIF1AN, EGLN3 MAPT 4747/4885STAT3 99/4885ALPL 3436/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.